Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK

References

• Henderson FW, Collier AM, Clyde WA Jr, et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300:530–534.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation Statement on immunisation for Respiratory Syncytial Virus.
   Google Scholar
• Public Health England. Immunisation against infectious disease (Green Book). Chapter 27a Respiratory syncytial virus. 2015.
   Google Scholar
• Cromer D, van Hoek AJ, Newall AT, et al. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2:e367–e374.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5:417–452.
   PubMed Web of Science ®Google Scholar
• Thwaites R, Buchan S, Fullarton J, et al. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland. Eur J Pediatr. 2020;179:791–799.
   PubMed Web of Science ®Google Scholar
• Hardelid P, Verfuerden M, McMenamin J, et al. The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015. Euro Surveill. 2019;24:1800046.
   Google Scholar
• Thwaites R, Coutts J, Fullarton J, et al., editors. Burden of respiratory syncytial virus hospitalisations (RSVH) over the first 2 years of life in children born <29 weeks' gestational age (WGA) European Society for Paediatric Infectious Diseases. Virtual meeting, 2020 Oct 26–29.
   Google Scholar
• Kugelman A, Colin AA. Late preterm infants: near term but still in a critical developmental time period. Pediatrics. 2013;132:741–751.
   PubMed Web of Science ®Google Scholar
• Luna M, Manzoni P, Paes B, et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020;33:35–44.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Perez-Yarza EG, Garcia LS, et al.; IRIS (Infección Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-the SPRING study. PloS One. 2015;10:e0125422.
   PubMed Web of Science ®Google Scholar
• Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir Med. 2018;6:257–264.
   PubMed Web of Science ®Google Scholar
• Fauroux B, Simoes EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6:173–197.
   PubMed Web of Science ®Google Scholar
• Coutts J, Fullarton J, Morris C, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020;55:1104–1110.
   PubMed Web of Science ®Google Scholar
• Skirrow H, Wincott T, Cecil E, et al. Preschool respiratory hospital admissions following infant bronchiolitis: a birth cohort study. Arch Dis Child. 2019;104:658–663.
   PubMed Web of Science ®Google Scholar
• Marlow R, Finn A, Henderson J. Assessing the association between bronchiolitis in infancy and recurrent wheeze: a whole English birth cohort case-control study. Thorax. 2019;74:503–505.
   PubMed Web of Science ®Google Scholar
• Henderson J, Hilliard TN, Sherriff A, et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16:386–392.
   PubMed Web of Science ®Google Scholar
• Shi T, Ooi Y, Zaw EM, et al.; RESCEU Investigators. Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis. 2020;222:S628–S633.
   PubMed Web of Science ®Google Scholar
• AbbVie Ltd. Summary of product characteristics: Synagis 100 mg/ml solution for injection. 2018.
   Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102:531–537.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540.
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Kusuda S, Okada K, et al.; Scientific Committee for Elucidation of Infantile Asthma. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study. Am J Respir Crit Care Med. 2017;196:29–38.
   PubMed Web of Science ®Google Scholar
• Igde M, Kabasakal H, Ozturk O, et al. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma. Minerva Pediatr. 2018;70:252–259.
   PubMed Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12:iii, ix-x, 1–86.
   Web of Science ®Google Scholar
• Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011;15:iii–iv, 1–124.
   PubMed Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss S, et al. The clinical and cost-effectiveness of Immunoprophylaxis against respiratory syncytial virus with palivizumab in children. Birmingham: Department of Public Health and Epidemiology West Midlands Health Technology Assessment Group University of Birmingham; 2007.
   Google Scholar
• Bentley A, Filipovic I, Gooch K, et al. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev. 2013;3:18.
   PubMedGoogle Scholar
• Sanchez-Luna M, Burgos-Pol R, Oyaguez I, et al. Cost-utility analysis of palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017;17:687.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Majer I, Garcia Roman N, et al. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Econ Rev. 2017;7:47.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Frederix GW, Nibbelke EE, et al.; Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr. 2018;177:133–144.
   PubMed Web of Science ®Google Scholar
• McGirr AA, Schwartz KL, Allen U, et al. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: a decision analysis model. Hum Vaccin Immunother. 2017;13:599–606.
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S. The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit. Heart. 2017;103:1746–1746.
   PubMed Web of Science ®Google Scholar
• Thwaites R, Edwards K, Buchan S. Reducing the burden of respiratory syncytial virus: an audit of the use of palivizumab prophylaxis in the UK during the September 2001–March 2002 RSV season. J Neonatal Nurs. 2008;14:116–123.
   Google Scholar
• de Souza RP, Ribeiro ALR, de Menezes SAF, et al. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil. BMC Pediatr. 2019;19:299–299.
   PubMed Web of Science ®Google Scholar
• Monteiro AIMP, Bellei NCJ, Sousa AR, et al. Respiratory infections in children up to two years of age on prophylaxis with palivizumab. Rev Paul Pediatr. 2014;32:152–158.por.
   PubMedGoogle Scholar
• Kim AY, Jung SY, Choi JY, et al. Retrospective multicenter study of respiratory syncytial virus prophylaxis in Korean children with congenital heart diseases. Korean Circ J. 2016;46:719–726.
   PubMed Web of Science ®Google Scholar
• Castillo LM, Bugarin G, Arias JC, et al. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America. J Pediatr. 2017;93:467–474.
   Google Scholar
• Office for National Statistics. Number of live births in the United Kingdom (UK) from 2000 to 2017 (in 1,000 births). 2018.
   Google Scholar
• Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89:673–678.
   PubMed Web of Science ®Google Scholar
• Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001;85:463–468.
   PubMed Web of Science ®Google Scholar
• Shefali-Patel D, Paris MA, Watson F, et al. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171:1055–1061.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95:500–505.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507.
   PubMed Web of Science ®Google Scholar
• Mac S, Sumner A, Duchesne-Belanger S, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review. Pediatrics. 2019;143:e20184064.
   PubMed Web of Science ®Google Scholar
• Notario G, Vo P, Gooch K, et al. Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group. Pediatr Health Med Ther. 2014;5:43–48.
   Google Scholar
• Anderson EJ, Carosone-Link P, Yogev R, et al. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36:699–704.
   PubMed Web of Science ®Google Scholar
• Papenburg J, Defoy I, Masse E, et al., editors. Impact of the withdrawal of palivizumab immunoprophylaxis on the incidence of respiratory syncytial virus hospitalizations among infants born at 33 to 35 weeks gestational age in the province of Quebec, Canada (RSV-QC Study). Poster session presented at: International Conference on Clinical Neonatology; 2019; Venice, Italy.
   Google Scholar
• Goldstein M, Krilov LR, Fergie J, et al. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012–2016. Amer J Perinatol. 2018;35:1433–1442.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Krilov LR, DeVincenzo JP, et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis. Am J Perinatol. 2017;34:51–61.
   PubMed Web of Science ®Google Scholar
• Thomas G. A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set. Eur J Health Econ. 2018;19:177–187.
   PubMed Web of Science ®Google Scholar
• Majer I, Pichardo-Pina CA, Sanchez-Casillas JL, et al. Cost-effectiveness of palivizumab in premature infants and children with chronic lung disease in Mexico. Value Health. 2015;18:A834.
   PubMed Web of Science ®Google Scholar
• Murray J, Bottle A, Sharland M, et al.; Medicines for Neonates Investigator Group. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PloS One. 2014;9:e89186.
   PubMed Web of Science ®Google Scholar
• Lin Y-J, Chung C-H, Chi H, et al. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study. Pediatr Res. 2019;86:628–634.
   PubMed Web of Science ®Google Scholar
• Checchia PA, Paes B, Bont L, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease. Infect Dis Ther. 2017;6:37–56.
   PubMed Web of Science ®Google Scholar
• Paes B, Fauroux B, Figueras-Aloy J, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther. 2016;5:453–471.
   PubMed Web of Science ®Google Scholar